CytomX Tax Provision from 2010 to 2024

CTMX Stock  USD 1.04  0.05  4.59%   
CytomX Therapeutics Tax Provision yearly trend continues to be fairly stable with very little volatility. Tax Provision is likely to outpace its year average in 2024. Tax Provision is the amount set aside by CytomX Therapeutics to cover any estimated taxes for the current period. It reflects CytomX Therapeutics' expected tax liabilities. View All Fundamentals
 
Tax Provision  
First Reported
2010-12-31
Previous Quarter
2.8 M
Current Value
M
Quarterly Volatility
5.4 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check CytomX Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CytomX Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.3 M, Interest Expense of 2.1 M or Selling General Administrative of 28.8 M, as well as many indicators such as Price To Sales Ratio of 1.07, Dividend Yield of 0.0299 or Days Sales Outstanding of 11.76. CytomX financial statements analysis is a perfect complement when working with CytomX Therapeutics Valuation or Volatility modules.
  
Check out the analysis of CytomX Therapeutics Correlation against competitors.
For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.

Latest CytomX Therapeutics' Tax Provision Growth Pattern

Below is the plot of the Tax Provision of CytomX Therapeutics over the last few years. It is the amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities. CytomX Therapeutics' Tax Provision historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CytomX Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Tax Provision10 Years Trend
Very volatile
   Tax Provision   
       Timeline  

CytomX Tax Provision Regression Statistics

Arithmetic Mean352,010
Geometric Mean0.00
Coefficient Of Variation1,544
Mean Deviation2,537,883
Median10,000
Standard Deviation5,434,250
Sample Variance29.5T
Range28.2M
R-Value0.03
Mean Square Error31.8T
R-Squared0.0007
Significance0.92
Slope32,686
Total Sum of Squares413.4T

CytomX Tax Provision History

2024M
20232.8 M
2021null
2020-13.9 M
2019-427 K
201814.3 M
2017-513 K

About CytomX Therapeutics Financial Statements

CytomX Therapeutics investors use historical fundamental indicators, such as CytomX Therapeutics' Tax Provision, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in CytomX Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Tax Provision2.8 MM

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for CytomX Stock Analysis

When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.